Yan, Wenqing <br/><br/>
Fenretinide targets the side population in myeloma cell line NCI-H929 and potentiates the efficacy of antimyeloma with bortezomib and dexamethasone regimen.  [electronic resource] 

 -  Leukemia research  12 2016 
 - 32-40 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-5835 
<br/><br/><label>Standard No.: </label>10.1016/j.leukres.2016.10.010  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Apoptosis<br/>Bortezomib--pharmacology<br/>Cell Line, Tumor<br/>Dexamethasone--pharmacology<br/>Fenretinide--pharmacology<br/>Humans<br/>Multiple Myeloma--drug therapy<br/>Neoplastic Stem Cells--drug effects<br/>Reactive Oxygen Species<br/>Side-Population Cells--drug effects